MedTrace Logo

Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.

NCT07781358 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-08-24

No results posted yet for this study

Summary

This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug vedotin combined with a PD-1 inhibitor. Following treatment, imaging assessment and surgical evaluation will be performed. Subjects deemed operable will undergo endoscopic nasal surgery, after which the MDT (multidisciplinary team) will discuss and determine a maintenance treatment plan. For subjects who are not eligible for surgery, the MDT will decide on either maintenance therapy or a switch to an alternative treatment regimen.

Conditions

  • Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG

Becotatug Vedotin

Becotatug vedotin 2.0 mg/kg, intravenous infusion, once every 3 weeks

DRUG

PD-1 / PD-L1 monoclonal antibody

PD-1 immune checkpoint inhibitor, administered according to the prescribing information of the investigator's chosen agent.

Sponsors & Collaborators

  • Hongmeng Yu

    lead OTHER

Principal Investigators

  • Kai Xue · Eye&ENT Hospital

  • Hongmeng Yu · Eye&ENT Hospital

  • Xiaole Song · Eye&ENT Hospital

  • Quan Liu · Eye&ENT Hospital

  • Li Yan · Eye&ENT Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-08-01
Completion
2029-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07781358 on ClinicalTrials.gov